References
[1] EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma[J]. J Hepatol, 2018, 69(1): 182-236.
[2] Heimbach J K, Kulik L M, Finn R S, et al. AASLD guidelines for the treatment of hepatocellular carcinoma[J]. Hepatology, 2018, 67(1): 358-380.
[3] Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018.
[4] Nguyen M H, Wong G, Gane E, et al. Hepatitis B Virus: Advances in Prevention, Diagnosis, and Therapy[J]. Clin Microbiol Rev, 2020, 33(2).
[5] Wong M, Huang J, George J, et al. The changing epidemiology of liver diseases in the Asia-Pacific region[J]. Nat Rev Gastroenterol Hepatol, 2019, 16(1): 57-73.
[6] Singal A G, Lampertico P, Nahon P. Epidemiology and surveillance for hepatocellular carcinoma: New trends[J]. J Hepatol, 2020, 72(2): 250-261.
[7] Finn R S, Qin S, Ikeda M, et al. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma[J]. N Engl J Med, 2020, 382(20): 1894-1905.
[8] Finn R S, Zhu A X. Evolution of Systemic Therapy for Hepatocellular Carcinoma[J]. Hepatology, 2020.
[9] Chen J, Hu X, Li Q, et al. Effectiveness and safety of toripalimab, camrelizumab, and sintilimab in a real-world cohort of hepatitis B virus associated hepatocellular carcinoma patients[J]. Ann Transl Med, 2020, 8(18): 1187.
[10] Yuan G, Cheng X, Li Q, et al. Safety and Efficacy of Camrelizumab Combined with Apatinib for Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: A Multicenter Retrospective Study[J]. Onco Targets Ther, 2020, 13: 12683-12693.
[11] Paul S, Saxena A, Terrin N, et al. Hepatitis B Virus Reactivation and Prophylaxis During Solid Tumor Chemotherapy: A Systematic Review and Meta-analysis[J]. Ann Intern Med, 2016, 164(1): 30-40.
[12] Chen C, Zhang F, Zhou N, et al. Efficacy and safety of immune checkpoint inhibitors in advanced gastric or gastroesophageal junction cancer: a systematic review and meta-analysis[J]. Oncoimmunology, 2019, 8(5): e1581547.
[13] Burns E A, Muhsen I N, Anand K, et al. Hepatitis B Virus Reactivation in Cancer Patients Treated With Immune Checkpoint Inhibitors[J]. J Immunother, 2021, 44(3): 132-139.
[14] Zhang X, Zhou Y, Chen C, et al. Hepatitis B virus reactivation in cancer patients with positive Hepatitis B surface antigen undergoing PD-1 inhibition[J]. J Immunother Cancer, 2019, 7(1): 322.
[15] Agarwal K, Brunetto M, Seto W K, et al. 96weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection[J]. J Hepatol, 2018, 68(4): 672-681.
[16] EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection[J]. J Hepatol, 2017, 67(2): 370-398.
[17] Lim C J, Lee Y H, Pan L, et al. Multidimensional analyses reveal distinct immune microenvironment in hepatitis B virus-related hepatocellular carcinoma[J]. Gut, 2019, 68(5): 916-927.
[18] Ho W J, Danilova L, Lim S J, et al. Viral status, immune microenvironment and immunological response to checkpoint inhibitors in hepatocellular carcinoma[J]. J Immunother Cancer, 2020, 8(1).
[19] Xuan H N, Thi M H P, Dinh T B, et al. Association of PD-L1 gene polymorphisms and circulating sPD-L1 levels with HBV infection susceptibility and related liver disease progression[J]. Gene, 2022, 806: 145935.
[20] Xu J, Shen J, Gu S, et al. Camrelizumab in Combination with Apatinib in Patients with Advanced Hepatocellular Carcinoma (RESCUE): A Nonrandomized, Open-label, Phase II Trial[J]. Clin Cancer Res, 2021, 27(4): 1003-1011.
[21] Deng H, Kan A, Lyu N, et al. Dual Vascular Endothelial Growth Factor Receptor and Fibroblast Growth Factor Receptor Inhibition Elicits Antitumor Immunity and Enhances Programmed Cell Death-1 Checkpoint Blockade in Hepatocellular Carcinoma[J]. Liver Cancer, 2020, 9(3): 338-357.
[22] Trehanpati N, Vyas A K. Immune Regulation by T Regulatory Cells in Hepatitis B Virus-Related Inflammation and Cancer[J]. Scand J Immunol, 2017, 85(3): 175-181.
[23] Loomba R, Liang T J. Hepatitis B Reactivation Associated With Immune Suppressive and Biological Modifier Therapies: Current Concepts, Management Strategies, and Future Directions[J]. Gastroenterology, 2017, 152(6): 1297-1309.
[24] El-Khoueiry A B, Sangro B, Yau T, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial[J]. Lancet, 2017, 389(10088): 2492-2502.
[25] Zhu A X, Finn R S, Edeline J, et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial[J]. Lancet Oncol, 2018, 19(7): 940-952.
[26] Sun X, Hu D, Yang Z, et al. Baseline HBV Loads Do Not Affect the Prognosis of Patients with Hepatocellular Carcinoma Receiving Anti-Programmed Cell Death-1 Immunotherapy[J]. J Hepatocell Carcinoma, 2020, 7: 337-345.
[27] Gane E, Verdon D J, Brooks A E, et al. Anti-PD-1 blockade with nivolumab with and without therapeutic vaccination for virally suppressed chronic hepatitis B: A pilot study[J]. J Hepatol, 2019, 71(5): 900-907.
[28] He M K, Peng C, Zhao Y, et al. Comparison of HBV reactivation between patients with high HBV-DNA and low HBV-DNA loads undergoing PD-1 inhibitor and concurrent antiviral prophylaxis[J]. Cancer Immunol Immunother, 2021.
[29] Zhang X, Zhou Y, Chen C, et al. Hepatitis B virus reactivation in cancer patients with positive Hepatitis B surface antigen undergoing PD-1 inhibition[J]. J Immunother Cancer, 2019, 7(1): 322.